ArticlePakistan journal of medical sciences2026
Efficacy of oral tapentadol immediate-release for the management of moderate-to-severe cancer pain in patients presenting to the oncology ward of a tertiary care hospital.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the efficacy and determine an effective dosing range of oral tapentadol immediate-release (IR) for managing chronic, moderate-to-severe pain in cancer patients in Pakistan, where extended-release formulations are not readily available. Methodology: This dose-response study was conducted at the Department of Medical Oncology, JPMC, Karachi over a one-week period. Forty-five patients were given 75 mg BID of oral tapentadol IR and the medication was titrated as necessary to achieve optimum analgesic effects. Pain before and after one week of commencing the medication was assessed by an 11-point Numeric Rating Scale. Patient satisfaction, adverse effects and dosage required to achieve adequate analgesia was noted. Data was analyzed using IBM SPSS version 23. Results: There was a significant decrease in the NRS score ( Conclusion: A starting dose of 75 mg BID of tapentadol IR led to a significant pain reduction in cancer patients with chronic pain in the Pakistani population, regardless of previous analgesic intake or cancer type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.